First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Conditions

• EGFR Mutation Positive Non Small Cell Lung Cancer

Interventions

• DRUG: Thymalfasin (Thymosin alpha 1, Ta1)
• DRUG: SoC (tyrosine kinase inhibitor)

Sponsor

SciClone Pharmaceuticals